Cytokinetics maintained at Outperform by RBC Capital
RBC Capital maintained its Outperform rating on Cytokinetics and raised its price target to $113 from $112, per Benzinga/TradingView.
Story updates
02:56:06 PM UTC
SquawkNews
Cytokinetics Is Maintained at Outperform by RBC Capital
02:56:20 PM UTC
SquawkNews
Cytokinetics Price Target Raised to $113.00/Share From $112.00 by RBC Capital